RhBSSL ( DrugBank: rhBSSL )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00743483 (ClinicalTrials.gov)	August 2008	26/8/2008	Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency	An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency	Cystic Fibrosis;Exocrine Pancreatic Insufficiency	Drug: rhBSSL	Swedish Orphan Biovitrum	NULL	Completed	18 Years	N/A	All	15	Phase 2	Netherlands;Poland
2	EUCTR2007-004063-21-NL (EUCTR)	24/07/2008	31/10/2007	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	Cystic fibrosis and pancreatic insufficiency MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: rhBSSL Product Code: rhBSSL INN or Proposed INN: Bucelipase alfa Trade Name: Nexium 20 Product Name: Nexium INN or Proposed INN: Esomeprazole	Biovitrum AB	NULL	Not Recruiting			Female: yes Male: yes	18		Netherlands